Exercised-based cardiac rehabilitation associates with lower all-cause mortality in patients with primary pulmonary hypertension.
| Autor: | Kleinnibbelink G; Research Institute for Sport and Exercise Sciences, Liverpool John Moores University, Liverpool, United Kingdom.; Research Institute for Health Sciences, Departments of Physiology and Cardiology, Radboud University Medical Center, Nijmegen, Netherlands., Buckley BJR; Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom.; Cardiovascular and Metabolic Medicine, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, United Kingdom., Harrison SL; Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom.; Cardiovascular and Metabolic Medicine, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, United Kingdom., Williams N; Department of Primary Care and Mental Health, University of Liverpool, Liverpool, United Kingdom., Fazio-Eynullayeva E; TriNetX LLC., Cambridge, MA, United States., Underhill P; TriNetX LLC., London, United Kingdom., van Dijk APJ; Research Institute for Health Sciences, Departments of Physiology and Cardiology, Radboud University Medical Center, Nijmegen, Netherlands., Lip GYH; Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom.; Cardiovascular and Metabolic Medicine, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, United Kingdom., Thijssen DHJ; Research Institute for Sport and Exercise Sciences, Liverpool John Moores University, Liverpool, United Kingdom.; Research Institute for Health Sciences, Departments of Physiology and Cardiology, Radboud University Medical Center, Nijmegen, Netherlands. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Frontiers in sports and active living [Front Sports Act Living] 2023 Dec 11; Vol. 5, pp. 1247615. Date of Electronic Publication: 2023 Dec 11 (Print Publication: 2023). |
| DOI: | 10.3389/fspor.2023.1247615 |
| Abstrakt: | Background: Despite pharmacological therapies to improve outcomes of pulmonary hypertension (PH), poor long-term survival remains. Exercised-based cardiac rehabilitation (ExCR) may be an alternative strategy to improve prognosis. Therefore, using an electronic medical record (EMR) database, the objective of this study was to compare mortality between patients with primary PH with ExCR vs. propensity-matched PH patients without ExCR. Methods: The retrospective analysis was conducted on February 15, 2023 using anonymized data within TriNetX, a global federated health research network. All patients were aged ≥18 years with primary PH recorded in EMRs with at least 1-year follow-up from ExCR. Using logistic regression models, patients with PH with an EMR of ExCR were 1:1 propensity score-matched with PH patients without ExCR for age, sex, race, and comorbidities, and cardiovascular care. Results: In total, 109,736 patients with primary PH met the inclusion criteria for the control group and 784 patients with primary PH met the inclusion criteria for the ExCR cohort. Using the propensity score-matched cohorts, 1-year mortality from ExCR was proportionally lower with 13.6% ( n = 101 of 744 patients) in the ExCR cohort compared to 23.3% ( n = 174 of 747 patients) in the controls (OR 0.52, 95% CI 0.40-0.68). Conclusion: The present study of 1,514 patients with primary PH suggests that ExCR is associated with 48% lower odds of 1-year mortality, when compared to propensity score-matched patients without ExCR. Competing Interests: BB has received funding from Bristol–Myers Squibb (BMS)/Pfizer. SH has received funding from BMS. EF-E and PU are employees of TriNetX LLC. AD has received speakers fees from Janssen. GL: consultant for Bayer/Janssen, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Novartis, Verseon and Daiichi-Sankyo and speaker for Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, and Daiichi-Sankyo. No fees are directly received personally. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (© 2023 Kleinnibbelink, Buckley, Harrison, Williams, Fazio-Eynullayeva, Underhill, van Dijk, Lip and Thijssen.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|